8-K: Grace Therapeutics: GTx-104 NDA Accepted, Q2 Results

Grace Therapeutics announced FDA acceptance of its New Drug Application for GTx-104 for aSAH, setting an April 23, 2026 PDUFA date, alongside its Q2 2026 financial results.

Summary

• The FDA accepted the New Drug Application (NDA) for GTx-104 for aneurysmal Subarachnoid Hemorrhage (aSAH) for formal review on August 22, 2025.
• The PDUFA target date for the FDA's decision on GTx-104 is April 23, 2026.
• Phase 3 STRIVE-ON safety trial data for GTx-104, which met its primary endpoint, was presented at the 2025 Neurocritical Care Annual Meeting.
• U.S. Patent No. 12,414,943 was issued on September 16, 2025, covering the IV dosing regimen for GTx-104, extending intellectual property protection to 2043.
• Approximately $4.0 million in additional funding was secured in October 2025 through exercises of common warrants from a September 2023 private placement, resulting in the issuance of 1,345,464 new shares of common stock at an exercise price of $3.003 per share.
• A net loss of $0.9 million, or $0.06 per share, was reported for the three months ended September 30, 2025, a decrease of $2.5 million from a net loss of $3.4 million, or $0.30 per share, for the same period in 2024.
• Total research and development expenses for the three months ended September 30, 2025, were $0.6 million, a $2.4 million decrease from $3.0 million in the prior year, primarily due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety trial.
• General and administrative expenses increased by $0.1 million to $2.0 million for the three months ended September 30, 2025, mainly due to costs for GTx-104 pre-commercial planning.
• Cash and cash equivalents were $16.9 million as of September 30, 2025, and an estimated $20.0 million as of October 31, 2025.
• Current cash and cash equivalents are expected to provide a cash runway through at least the next twelve months, with potential extension into the second quarter of calendar 2027 if all common warrants from the February 2025 private placement (potential gross proceeds of $15.0 million) are exercised.
• The development of GTx-102 and GTx-101 has been deprioritized to focus on GTx-104, with potential licensing or sale of these assets.

Sentiment

Score: 8

Explanation: The filing presents very strong positive developments with the FDA acceptance of the NDA for GTx-104, positive Phase 3 trial results, extended patent protection, and a clear PDUFA date. While there is a net loss, it has decreased, and the cash runway is adequate, supported by recent warrant exercises. The deprioritization of other assets is a strategic focus on the lead candidate. The only minor negative is the higher number of deaths in the GTx-104 arm, but this was attributed to underlying disease severity.

Positives

• The FDA accepted the New Drug Application (NDA) for GTx-104 for aSAH, marking a significant regulatory milestone.
• A PDUFA target date of April 23, 2026, has been established, providing a clear timeline for potential market approval.
• The Phase 3 STRIVE-ON trial met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension for GTx-104 compared to oral nimodipine.
• STRIVE-ON trial data also showed improved 90-day functional outcomes (+29% relative increase in good recovery), better relative dose intensity (54% vs. 8% for oral nimodipine), and significant pharmacoeconomic benefits (1.5 fewer ICU days, 5 fewer ventilator days, 48% reduced ICU readmissions).
• A new U.S. Patent (No. 12,414,943) was granted for GTx-104's IV dosing regimen, strengthening intellectual property and extending protection to 2043.
• GTx-104 has Orphan Drug Designation from the FDA, providing seven years of marketing exclusivity in the United States upon approval.
• The net loss for Q2 2026 significantly decreased to $0.9 million from $3.4 million in Q2 2025.
• Research and development expenses decreased by $2.4 million, reflecting the completion of the pivotal Phase 3 trial.
• The company secured $4.0 million in additional funding from warrant exercises in October 2025.
• The cash runway is projected through at least the next twelve months, with potential extension into Q2 2027 if all outstanding warrants are exercised.

Negatives

• The company reported a net loss of $0.9 million for the three months ended September 30, 2025.
• Cash and cash equivalents decreased by $5.2 million from $22.1 million at March 31, 2025, to $16.9 million at September 30, 2025.
• General and administrative expenses increased by $0.1 million, primarily due to pre-commercial planning costs for GTx-104.
• The STRIVE-ON trial reported 8 deaths in the GTx-104 arm compared to 4 deaths in the oral nimodipine arm, although all deaths were attributed to the severity of the underlying disease and not the drug.
• The development of GTx-102 and GTx-101 has been deprioritized, indicating a narrower focus on the lead candidate and potentially limiting future pipeline diversity.

Risks

• The success and timing of regulatory submissions and the ultimate outcome of the NDA application for GTx-104 are uncertain.
• Regulatory requirements or developments may change, impacting the approval process or market access for GTx-104.
• The company's ability to protect its intellectual property for its drug candidates, including GTx-104, is crucial for long-term market value.
• Legislative, regulatory, political, and economic developments could adversely affect the company's operations and financial performance.
• The company's cash runway and cash position are dependent on future events, including the exercise of outstanding warrants.
• The commercial prospects of GTx-104, including market acceptance, pricing, and competition, may not meet expectations.
• Actual results and the timing of events could differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company anticipates continued engagement with the FDA leading up to the PDUFA target date of April 23, 2026, for GTx-104. They are also undertaking pre-commercial planning for GTx-104. The current cash and cash equivalents are expected to provide a runway through at least the next twelve months, with potential extension into the second quarter of calendar 2027 if all February 2025 common warrants are exercised. The company plans to continue building its patent portfolio.

Management Comments

• "During our second quarter of 2026 we continued to execute on our clinical and corporate goals, led by FDA acceptance for review of our NDA for GTx-104 for the treatment of aSAH."
• "Acceptance of our NDA for review is another significant milestone for the Company and further demonstrates our ability to execute as we continue to advance this important innovation for aSAH patients."
• "Our NDA is supported by a robust data package including positive results from our STRIVE-ON trial, which provided evidence of improved clinical outcomes in aSAH patients treated with GTx-104 as well as potential medical and pharmacoeconomic benefits of GTx-104 in the treatment of aSAH."
• "We were pleased to see these data highlighted in a presentation at the Neurocritical Care annual meeting, where the results were well received by the conference attendees."
• "This new patent coverage on the dosing regimen should be included in the label for GTx-104 if it is approved by the FDA, adding a new layer and extending the duration of our intellectual property protections."
• "We believe that if our NDA for GTx-104 is approved by the FDA, our strong U.S. and international patent estate will help to maximize the long-term market value of GTx-104 and correspondingly deliver value for our shareholders."
• "The standard of care for aSAH has not seen meaningful innovation in nearly 40 years, and we believe that if GTx-104 is approved, our STRIVE-ON trial results point to a very promising role for GTx-104 in the treatment of these patients."
• "We look forward to continuing to engage with the FDA during their review as they work toward the PDUFA target date of April 23, 2026."

Industry Context

Aneurysmal Subarachnoid Hemorrhage (aSAH) is a severe and relatively uncommon type of stroke with high mortality and disability rates, for which oral nimodipine has been the standard of care for over three decades. However, oral nimodipine presents significant challenges in administration, inconsistent therapeutic benefit, and risks of medication errors. Grace Therapeutics' GTx-104, an intravenous formulation, aims to address these unmet needs by offering improved tolerability, consistent drug delivery, and potential pharmacoeconomic advantages, positioning it to potentially replace the current oral standard of care. The concentrated nature of aSAH patient care in specialized institutions allows for an efficient commercialization strategy.

Comparison to Industry Standards

• GTx-104's Phase 3 STRIVE-ON trial demonstrated a 19% reduction in clinically significant hypotension compared to oral nimodipine, which is the current standard of care for aSAH.
• The trial showed that 54% of GTx-104 patients achieved a relative dose intensity of 95% or higher, significantly outperforming the 8% observed with oral nimodipine, indicating superior dose compliance.
• GTx-104 was associated with a 29% relative increase in patients achieving good functional outcomes at 90 days compared to oral nimodipine.
• Pharmacoeconomic outcomes favored GTx-104, with patients experiencing 1.5 fewer ICU days, 5 fewer ventilator days, and a 48% reduction in ICU readmissions compared to those on oral nimodipine.
• The company highlights that GTx-104's improved administration method (IV infusion) could enhance adherence to care guidelines monitored by bodies like The Joint Commission, addressing known challenges with oral nimodipine's high dosing burden and administration difficulties (e.g., via nasogastric tube).

Stakeholder Impact

• Shareholders: Potential for significant value creation upon GTx-104 approval, enhanced by extended IP protection and a clear regulatory pathway. Recent capital infusion from warrant exercises provides financial stability.
• Patients (aSAH): Potential for a new, improved treatment option (GTx-104) that addresses the limitations of current oral nimodipine, potentially leading to better clinical outcomes, reduced complications, and improved quality of life.
• Healthcare Providers: GTx-104 offers easier and more consistent administration (IV infusion), potentially reducing nursing burden, medication errors, and improving patient management in critical care settings.
• Creditors: Improved financial outlook and potential for future revenue streams from GTx-104 approval enhance the company's creditworthiness.

Next Steps

• Continue to engage with the FDA during their review of the GTx-104 NDA.
• Await the FDA's decision on GTx-104 by the PDUFA target date of April 23, 2026.
• Proceed with pre-commercial planning activities for GTx-104.
• Potentially license or sell the deprioritized GTx-102 and GTx-101 assets.
• Continue building the patent portfolio by filing for patent protection on new developments.

Key Dates

Recommendation

The FDA's acceptance of the NDA for GTx-104, coupled with a clear PDUFA date, represents a pivotal de-risking event for Grace Therapeutics. The robust positive Phase 3 STRIVE-ON trial data, demonstrating superior clinical and pharmacoeconomic benefits over the current standard of care, strongly positions GTx-104 for approval. The extended patent protection and Orphan Drug Designation further enhance the long-term commercial potential. While the company is currently operating at a loss, the significant reduction in net loss, controlled R&D expenses, and a projected cash runway extending into 2027 (with potential warrant exercises) provide financial stability. The strategic focus on GTx-104, a potential first-in-class IV nimodipine for a severe unmet medical need, suggests substantial upside potential upon market approval. This filing indicates a strong trajectory towards commercialization and significant value creation.

Keywords

Grace Therapeutics, GRCE, GTx-104, aSAH, aneurysmal Subarachnoid Hemorrhage, nimodipine, FDA, NDA, PDUFA, biopharma, clinical trial, STRIVE-ON, patent, orphan drug, financial results, Q2 2026, cash runway, warrant exercise